Introduction
============

For a long time, gene regulatory network has been mainly focusing on protein coding genes [@B1]. However, the fact that about 90% of the human genome is transcribed at specific time points during the development yet only 1% is protein coding, suggests that abundant remaining gene sequences are still unknown [@B2]. Although they were considered as junk in the past, recent studies have revealed that these noncoding transcripts, which are lowly-expressed, unstable and poorly conserved, play a significant role in the evolution process. Due to the rapid development of high-throughput RNA sequencing technology, a vast number of new noncoding RNAs have been uncovered. Recent studies have also shown that some of these noncoding RNAs play vital regulatory roles in multiple biological processes. Nonetheless, the precise biological function is still far from understood due to their complexity [@B3]. Noncoding RNAs can be divided by their size into small noncoding RNAs (\< 200 nucleotides), which include miRNAs, transfer RNAs and small nucleolar RNAs, and long noncoding RNAs (\> 200 nucleotides), which include long intergenic noncoding RNAs, intronic lncRNAs, bidirectional lncRNAs, sense lncRNAs, antisense lncRNAs, and enhancer RNAs according to the adjacent protein-coding genes. LncRNAs can be further distinguished by their cellular location to nucleus or cytoplasm and by their action type to *in cis* or*in trans*. Notably, the distinction is not very clear that some lncRNAs may locate in both nucleus and cytoplasm or work both using *in cis* and *in trans* dogma [@B2], [@B3]. The majority of lncRNAs are located in the nucleus with only 15% in the cytoplasm [@B4]. For the nuclear lncRNAs, most show transcriptional repression effects by guiding chromatin modifiers like PRC2 to specific genomic targets [@B3]. Khalil *et al.*, suggest that about 20% of lincRNAs are bound by PRC2 [@B5]. *Xist* is the typical example which involves in X-chromosome inactivation. It specifically captures PRC2 through a conserved repeat motif and takes it to the inactive X chromosome with the help of YY1 protein, which binds both*Xist* and the target gene loci, thus initiating X-chromosome inactivation*in cis* [@B6], [@B7]. It could also act *in trans* to inactivate the distal X-chromosome by identifying the three-dimensional structure of the X-chromosome [@B8]*. Fendrr* specifically binds to PRC2 and guides PRC2 to the promoters of *Foxf1 in cis*and *Pitx2 in trans* [@B9]. *ANRIL* could work as a scaffold to bind both PRC1 and PRC2 to repress its targets [@B10]. LncRNAs could also indirectly regulate target genes by acting as a decoy to sequester regulatory factors, *e.g. MALAT1* works as a decoy to trap and accumulate specific splicing factors in nuclear speckles. The knocking-down of *MALAT1* results in homogeneous distribution of splicing factors in the nucleus thus inhibiting pre-mRNA alternative splicing *in trans* [@B11]. For cytoplasmic lncRNAs, most of them regulate on translation level by base pairing with their targets [@B3]. One of the targets is miRNAs. These lncRNAs are also called ceRNAs which act like sponges to prevent miRNAs from binding to their targets. *CARL* functions mainly in cytoplasm and works as a sponge to target miR-539 thus blocking its repression on *Phb2* [@B12]. In some cases, lncRNAs serve as the precursor gene of miRNAs with which they are co-transcribed. Some studies show that knocking down the lncRNA could concomitantly influence miRNA transcription [@B13]. Other studies also indicate that lncRNAs could regulate miRNAs on transcriptional levels. *HULC* down-regulates miR-9 by inducing methylation of the miR-9 promoter [@B14]. Another target is mRNA, *LincRNA-p21*targets *CTNNB1* and *JUNB* mRNAs and represses them [@B15]. *TINCR* can influence the stability of its target mRNA to modulate its expression [@B16]. LncRNAs could also be co-activators or enhancers by acting as essential elements in target gene activation. *Jpx* knocking-down inhibits *Xist* activation and expression of *Jpx* rescues *Xist* activation [@B17]. *SRA* is a component of a ribonucleoprotein complex which contains the typical co-activator protein SRC-1 and *SRA* works as a RNA co-activator to selectively enhance transcriptional activation [@B18]. LncRNAs could specifically bind to other proteins rather than chromatin modifiers. *LincRNA-p21* binds with hnRNP-K and guides it to the promoters of *p53* target genes thus suppressing *p53* target genes [@B19]. *LincRNA-p21*also binds to MDM2 thus enhancing *p53* activities [@B20]. It is therefore obvious that the regulatory roles of lncRNAs are complicated due to abundant unknown areas. Yet, exiting data have already indicated that lncRNAs may selectively bind with proteins, mRNAs or miRNAs to sequester or guide them to target genes to participate in various cellular and molecular regulations. Importantly, as many lncRNAs are poorly conserved between different species even different cells, they may serve as potential cell specific targets.

Although the mortality rate has declined, cardiovascular disease is still the leading cause of death worldwide. In 2011, cardiovascular disease accounts for one out of every three deaths in the United States. Medical cost for cardiovascular diseases is still a heavy economic burden [@B21]. Atherosclerosis concerns the fundamental vascular change in cardiovascular diseases. Previous studies have shown that atherosclerosis is a combination of lipid disorder and chronic inflammatory disease [@B22]. Endothelial cell dysfunction caused by oxidative, hemodynamic, or biochemical stimuli initiates the progress of atherosclerosis. Following that, EC\'s permeability changes and macrophages start to accumulate and release inflammation factors. Smooth muscle cells are then activated and begin proliferation and migration. Therefore, the pathogenesis of atherosclerosis is a result of various changes and interactions in multiple cell types in the artery walls which mainly includes lipid deposition, endothelial cell dysfunction, macrophages activation, and SMC alternation [@B22]. As a deadly disease, new cellular and molecular mechanisms are urgent to find in order to provide novel therapeutic targets.

Previous reports have shown that miRNAs play a significant role in the development of atherosclerosis [@B23]. Due to the various functions of lncRNA and its regulatory role as the ceRNA, it may be reasonable to speculate that lncRNAs may directly or indirectly contribute to the development of cardiovascular disease and atherosclerosis. This review will thus summarize the current findings of lncRNAs in atherosclerosis-related cells and provide an overview of lncRNA\'s regulation in atherosclerosis.

LncRNAs in SMC regulation
=========================

The proliferation and migration of SMCs are thought to be the key events in atherosclerotic lesion progression and restenosis. At the initial stage of atherogenesis, SMCs switch their phenotype from contractile to synthetic and move into the intima resulting in intimal hyperplasia [@B24], [@B25]. A number of studies have examined the potential function of lncRNAs in SMC\'s proliferation and migration.

The chromosome 9p21 locus SNPs have been reported to increase the risk of atherosclerosis and myocardial infarction [@B26], [@B27]. The nearest protein-coding gene of the 9p21 locus is *CDKN2A/B* which encodes cell proliferation regulators: *p16^INK4a^*, *p14^ARF^* and *p15^INK4b^*. Motterle *et al.*find that the 9p21 locus risk SNPs promote VSMC proliferation and reduce *p16^INK4a^ and p15^INK4b^* expressions in VSMCs. Furthermore, in atherosclerotic lesions, there are lower levels of *p15^INK4b^* expression and higher levels of VSMC proliferation [@B28]. This and some other studies also suggest that the 9p21 locus risk SNPs influence the long noncoding RNA *ANRIL* transcription which overlaps the region [@B29]. The risk SNPs increase the expression of *ANRIL* transcripts both in plaque and peripheral blood. Meanwhile, *ANRIL* is closely associated with the severity of atherosclerosis [@B30]. Further studies demonstrate that *ANRIL* regulates VSMC growth through *CDKN2A/B*. The knocking-down of *ANRIL* in VSMC increases the expression of *CDKN2B* and inhibits VSMC proliferation [@B28], [@B31]. Kotake*et al.* prove that *ANRIL* binds to SUZ12, a component of PRC2, and recruits it to *p15^INK4b^* thus repressing *p15^INK4b^* expression by RNA immunoprecipitation. Using similar technology, Yap and colleagues report another mechanism through which *ANRIL* interacts with CBX7, a component of the PRC1 thus repressing *p16^INK4a^* whereas *p15^INK4b^* is not affected [@B32], [@B33]. Although there are conflicting binding proteins and functions, *ANRIL* inhibits *CDKN2A/B* expression in the end and reduces cell growth. Despite the *cis* effect, Sato *et al.* suggest a *trans* effect by overexpressing *ANRIL* and find some regulated genes *in trans* in HeLa and lung tumour cells [@B34]. Holdt and co-workers, through the gain and loss of function analysis, further prove that the regulated genes *in trans* are associated with proliferation, cell adhesion, and apoptosis and *ANRIL* regulates these genes probably by recruiting CBX7 and SUZ12 to the promoters *in trans* [@B35]. Finally, it is still uncertain whether *ANRIL* regulates VSMC proliferation through the mechanisms mentioned above as these studies are conducted in tumour cells. *ANRIL\'s* exact mechanism in VSMC needs further investigation. Nonetheless,*ANRIL* has been proved to regulate *CDKN2A/B* in VSMC and has revealed a strong regulatory function in VSMC proliferation. As a potential atherosclerosis risk factor and therapeutic target, future studies may concentrate on the circulating *ANRIL* for biomarkers of atherosclerosis severity and the plaque\'s *ANRIL* for pharmacological targets.

The *H19* gene is a well-known imprinted gene important in cell differentiation and growth. Its noncoding RNA transcript is *H19 lincRNA*and *H19 lincRNA* is the precursor of miR-675. *H19 lincRNA* has been found to enhance or weaken tumour growth and invasion, respectively, in different types of tumours [@B36]-[@B38]. *H19 lincRNA* is also highly expressed in neointima after injuries and human atherosclerotic lesions but barely expressed in normal arteries [@B39], [@B40]. Gao and co-workers examine the polymorphisms in *H19* and find that individuals carrying the risk alleles of *H19* display a higher risk of coronary artery disease [@B41]. It is thus reasonable to assess *H19 lincRNA*\'s role in atherosclerosis. MiR-675 is encoded by *H19 lincRNA* and previous studies indicate that *H19 lincRNA* controls the expression of miR-675 in regulating the growth of placenta [@B42]. Recent studies suggest that*H19 lincRNA* functions as a sponge of the let-7 family miRNA and let-7 miRNAs have been indicated to protect VSMC from oxidative damage [@B43], [@B44]. Whether *H19 lincRNA* regulates SMC through the let-7 pathway or by miR-675, thus promoting atherosclerosis is still ambiguous. More studies are warranted to assess the relationship between *H19 lincRNA* level and the plaque severity. Furthermore, more precise mechanism under *H19 lincRNA* in VSMC is needed. Leung*et al.* conduct an RNA-seq of Ang II-stimulated VSMC and identify a novel lncRNA named *Lnc-Ang362* which may promote VSMC proliferation [@B45]. It is the host gene of miR-221 and miR-222 which have been proven to be regulators in VSMC proliferation and neointimal hyperplasia [@B46]. Knocking-down of *Lnc-Ang362* reduces miR-221 and miR-222 expression and inhibits SMC proliferation. Therefore, *Lnc-Ang362* could promote VSMC proliferation through these two miRNAs. [@B45].

*p53*is a tumour repressor gene involved in cell proliferation and apoptosis. Previous studies also indicate that*p53* plays an important role in atherosclerosis progression [@B47]. Recent studies reveal that *lincRNA-p21*is controlled by*p53*. *LincRNA-p21* directly binds with hnRNP-K and guides it to the promoters of *p53* repressed genes thus involves in *p53* downstream repression [@B19]. Cytoplasmic *lincRNA-p21* also modulates translation process by direct binding to its target mRNAs [@B15]. Wu *et al.* further identify the role for*lincRNA-p21* in SMC proliferation and apoptosis by revealing a novel mechanism. The direct binding between *lincRNA-p21* and the protein of a *p53*downstream gene *MDM2* is firstly observed. Knocking-down of *lincRNA-p21*changes the balance between MDM2/p53 complex and p300/p53 complex and as a result, suppressing *p53* activity*.* Above all, *p53* regulates SMC proliferation and apoptosis in a *lincRNA-p21*dependent manner. *In vivo*, siRNA-induced *lincRNA-p21* inhibition stimulates SMC proliferation and neointimal hyperplasia. Clinical findings also reveal that coronary tissues from CAD patients exhibit a reduced level of *lincRNA-p21* compared to aorta tissues from non-CAD patients [@B20]. Similar to *ANRIL* and *H19 lincRNA*which have been tested in lesion area,*lincRNA-p21* may also serve as a potential biomarker of atherosclerosis and a therapeutic target.

Hyaluronan is an important component of the arterial walls and excess hyaluronan enhances atherosclerosis progression [@B48]. Recent findings show both *HAS2* and *HAS2-AS1*, which is an antisense transcript of *HAS2* are related to the severity of atherosclerosis. *HAS2* and *HAS2-AS1* are modulated under metabolic disorders like diabetes. Using nuclease accessibility assays, Vigetti *et al.* find that hyperglycemic stress induces *HAS2-AS1* expression and *HAS2-AS1* transcripts could identify specific region on*HAS2* and bring chromatin modifiers to the promoters of *HAS2* thus up-regulating *HAS2* transcription *in cis* [@B49]. The exact chromatin modifier is still unknown but targeting artery substrate is an important aspect in preventing atherosclerosis progression.

More other lncRNAs are also found to be associated with SMC although studies on these lncRNAs are still limited. Zhao *et al.* screen differentially expressed lncRNAs in patients of aorta aneurysm and find *HIF1α-AS1*. By knocking down *HIF1α-AS1* in SMC, apoptosis and apoptosis-related proteins are down-regulated in SMC indicating its role in SMC apoptosis [@B50]. Li *et al.* screen lncRNAs in varicose veins and find *lncRNA-GAS5*. *In vitro* studies depict that it may inhibit proliferation, migration and cell cycle of SMC. Furthermore, Li*et al.* identify a direct binding between *lncRNA-GAS5* and the protein Annexin A2. Overexpressing Annexin A2 could block *lncRNA-GAS5*\'s function on proliferation and migration [@B51]. Bell *et al.* find a new lncRNA called *SENCR* through the RNA-seq of SMC. It is an antisense of *FLI1* but there is no *cis* effect on it. Instead, reduced *SENCR* could down-regulate contractile related genes (*Myocd*) and up-regulate migratory genes (*Mdk and Ptn*) *in trans*. Therefore, *SENCR* promotes a synthetic SMC phenotype and cell migration [@B52].

Overall, a growing number of studies have reported that lncRNA is capable of regulating proliferation, migration and matrix synthesis in SMC, all of which participate in different aspects of lesion formation. To this end, interventions targeting specific lncRNAs may suppress lesion development and luminal stenosis. Some of these lncRNAs have already been identified in lesion area and display an association with the severity of atherosclerosis. However, the research on a wide set of newly identified lncRNAs and their regulating pathways are still in its infancy. Meanwhile, mining the abundant remaining sequence data from RNA sequencing results is a promising approach to identify new gene regulators.

LncRNA in EC function
=====================

Endothelial dysfunction stemmed from EC injury represents an early step in the onset and development of atherosclerosis. Injured ECs result in increased permeability and accumulation of adhesion proteins, thereby stimulating migration of leukocytes into the vessel walls [@B22]. A unique role for LncRNA in ECs has been depicted, many of which indicate that lncRNAs may regulate EC functions especially in angiogenesis. Further evidence reveals that lncRNAs are induced in hypoxic or hyperglycemic conditions which should provide new theory to regulate EC injuries.

NFAT plays a significant role in cardiac valvular formation. Upon stimulation, NFAT is dephosphorylated and moves into the nucleus to function as a transcriptional factor [@B53]. The long noncoding RNA *NRON* is identified as a new cytoplasmic lncRNA which comprises a NRON complex by binding to KPNB1/PPP2R1A/PSMD11/IQGAP1. *NRON* acts as a decoy to trap NFAT thus inhibiting NFAT\'s nuclear distribution [@B54], [@B55]. Ets-1 could accumulate in the cytoplasm and competitively displace NFAT from the *NRON*complex thus weakening *NRON*\'s function [@B56]. Tang *et al.* investigate *NRON*\'s role in ECs through the gain and loss of function analysis and find that *NRON* overexpression inhibits *NFAT* expression which reduces ECs\' proliferation, tube formation and migration. On the other hand, siRNA-induced *NRON* inhibition results in activation of *NFAT* which promotes ECs\' proliferation, tube formation, and migration [@B57]. Another lncRNA which may participate in vessel formation is *Tie-1 AS*. *Tie-1* was previously found to be important in vessel formation [@B58]. Li *et al.*find that *Tie-1 AS* and *Tie-1* transcripts are expressed in a manner reminiscent of zebrafish embryonic development indicating its role in *Tie-1* regulation. By bioinformatics and hybridisation analysis, Li*et al.*further confirm that *Tie-1 AS* binds to *Tie-1* mRNA to down-regulate*Tie-1* translation. In HUVECs, *Tie-1 AS*overexpression inhibits *Tie-1*, thus affecting tube formation [@B59]. Recently, three new lncRNAs are identified in EC\'s differentiation and angiogenesis. During the process when the pluripotent stem cell differentiates to ECs, three novel lncRNAs are significantly induced. *Terminator* is mainly expressed in pluripotent stem cell period, while *Alien* and *Punisher* are specifically expressed in cardiovascular progenitors and endothelial cells, respectively. In mice and zebrafish, similar trends are found. Loss of function analysis shows that *Terminator*knockdown mainly influences genes related to pluripotent maintenance. *Alien* knockdown mainly affects cell adhesion, extracellular matrix remodelling, angiogenesis and blood vessel development.*Punisher*knockdown mainly impacts mitosis, cell adhesion and extracellular interaction.*In vitro* analysis of *Punisher*knockdown shows that EC proliferation and tube formation are significantly reduced [@B60]. *NRON*,*Tie-1 AS*and *Punisher*are involved in EC tube formation through different mechanisms. Due to their essential roles in angiogenesis, these lncRNAs might be potential regulators in neovascularization.

*MALAT1*was firstly identified in lung cancer [@B61]. Later, increased *MALAT1* levels are found in several other types of tumours and overexpression of *MALAT1* results in proliferation and metastasis [@B62], [@B63]. Recent studies show that *MALAT1* are induced in stressful conditions like hypoxia and hyperglycemia in ECs [@B64]-[@B66]. *MALAT1*plays a significant role in alternative splicing of pre-mRNAs by maintaining specific splicing factors in the nuclear speckles. Depletion of *MALAT1*results in homogeneous distribution of SR proteins and higher ratios of dephosphorylated SR proteins. In a word, *MALAT1* regulates alternative splicing by controlling the distribution and activity of SR proteins [@B11], [@B67]. In ECs, Michalik *et al.* find that the expression of *MALAT1* is significantly induced in hypoxia-treated HUVEC and that silencing *MALAT1*promotes EC\'s migration, sprouting and inhibits EC proliferation. *In vivo* studies reveal that both neovascularization in the retina and capillary density after hind limb ischemia are reduced in *MALAT1*knockout mice. Microarray analysis following knocking down *MALAT1* shows that cell cycle regulators such as *CCNA2*, *CCNB1*, and *CCNB2* are down-regulated and *p21*, *p27Kip1* are increased. There is little sign of splicing-related genes getting affected [@B64]. In diabetic mice, *MALAT1*expression is up-regulated in retinas and kidneys and silencing *MALAT1* is found to inhibit diabetic retinopathy such as pericyte loss, capillary degeneration and microvascular leakage. In ECs stimulated with hyperglycemia, *MALAT1*is found not only involved in angiogenesis but also in inflammation. The knocking-down of *MALAT1* decreases the proliferation, migration, and tube formation in hyperglycemic ECs. Meanwhile, inflammation factors such as IL-6 and TNF-α are also reduced [@B65], [@B66]. These studies show conflicting results with Michalik *et al.* in*in vitro*studies especially in migration result which is probably because different cell types (HUVEC and retinal endothelial cell) and stimuli. Nonetheless it is obvious that *MALAT1* plays an essential role in macro- and micro-vascular angiogenesis by regulating EC in stressful conditions*.*As*MALAT1*is also induced in stressful stimuli, there is a possible link between *MALAT1* and the severity of EC injury. Meanwhile, targeting *MALAT1* is a new approach to reduce diabetic retinal neovascularization and inflammation. *MIAT* has been found to be associated with myocardial infarction previously [@B68]. Recently, it is also found involved in diabetic microvascular disease. *MIAT* level is up-regulated in diabetic retinas and hyperglycemic ECs. *MIAT* knockdown could also inhibit EC proliferation, migration, and tube formation. *In vivo* analysis shows that *MIAT* knockdown attenuates diabetes-induced pericyte loss, capillary degeneration and microvascular leakage. But the underlying mechanism is miR-150 dependent. VEGF is the repression target of miR-150. *MIAT* up-regulates VEGF by working as a decoy to suppress miR-150 [@B69]. *LincRNA-p21*, like its role in SMC, also up-regulates EC apoptosis and inhibits cell cycle but the underlying mechanism is a sponge of miR-130b [@B70]. Another sponge lncRNA is *FLJ11812*. Ge *et al.*investigate the role of *FLJ11812* following a microarray analysis with 3DBO-treated ECs. Through luciferase assay, *FLJ11812* is proved to target miR-4459 as a sponge. ATG13 is the repression target of miR-4459. Via the *FLJ11812*/miR4459/ATG13 pathway, *FLJ11812* could regulate ATG13 levels thus involving in autophagy in the 3DBO downstream pathways [@B71]. Reduced nitric oxide synthase levels have been found in atherosclerosis. One of the nitric oxide synthase, which is specially expressed in endothelial cells, termed *eNOS*, is a key regulator in vascular wall homeostasis [@B72], [@B73]. Robb *et al.* thus investigate the regulation of *eNOS* and report an antisense transcript to *eNOS* called *sONE*. It is interesting because *sONE* is expressed in various types of cells except ECs in normal conditions. Through the gain and loss of function analysis in ECs, *sONE* is found to reduce *eNOS* protein but not the mRNA levels indicting its role in posttranscriptional regulation. A lower level and stability of *eNOS* mRNA is observed in hypoxia ECs, and *sONE* is reciprocally expressed in hypoxia stimuli [@B72]. It is reasonable to confer that *sONE* plays a role in regulating *eNOS* in this process. Fish *et al.* find that hypoxia induces *sONE* by increasing its RNA stability rather than its transcription regulation. In addition, hypoxia induces *sONE* cytoplasmic accumulation. *sONE* knockdown reduces the attenuation of *eNOS* mRNA during hypoxia [@B74]. Targeting sONE could be a new approach to increase *eNOS* thus maintaining vascular homeostasis.

Currently, lncRNAs are involved in EC proliferation, tube formation and migration. Some lncRNAs are angiogenesis regulators under normal conditions, while others also function under hypoxic or hyperglycemic stress which may stimulate atherosclerosis process more aggressively. For those with stressful stimuli, there remains the possibility to use them as biomarkers for early EC injury or new molecular targets for EC injury regulation. The two very important lncRNAs *MALAT1* and *MIAT*are induced in diabetic retinal disease and targeting them could reduce the retinal vessel impairment and ameliorate retinal function.

LncRNA in macrophage and immunity
=================================

Atherosclerotic lesion is composed of accumulation of lipoproteins, macrophages-derived foam cells within the arterial wall. Macrophages are activated and move into the vessel wall, devour cholesterol to form foam cells, and then release inflammatory factors thus exacerbating macrophage accumulation [@B22]. This suggests that there is a linkage between lipid metabolism and innate immune response. It is important to find new targets in cellular lipid transport and immunity. Although only a few macrophage-related lncRNAs are identified, researchers have revealed their significant regulatory role in macrophages and inflammation.

Cellular lipid mechanism especially in foam cells is an important issue in atherosclerosis progress. Hu *et al.* find that lncRNA is a novel regulator in cholesterol metabolism and inflammation. Through microarray analysis, Hu*et al.* try to identify the expression profile of macrophages and macrophage-derived foam cells. *LincRNA-DYNLRB2-2* and *lncRNA RP5-833A20.1* are greatly induced during this process, both of which could regulate cellular cholesterol metabolism and inflammation, but in different pathways. *LincRNA-DYNLRB2-2* decreases cellular inflammatory cytokines (TNF-α, IL-1β and IL-6) and promotes cholesterol efflux in macrophages under hyperlipidemic stress. Further studies show that *lincRNA-DYNLRB2-2*regulates ABCA1, which is an important role in the efflux of cellular lipid, in a *GPR119*-dependent manner [@B75]. Another long noncoding RNA *RP5-833A20.1* is located in intron 2 of the *NFIA* gene and an antisense of it. It increases inflammatory cytokines (TNF-α, IL-1β and IL-6) and reduces cholesterol efflux via the miR-382-mediated *NFIA* pathway. Further studies show that ABCA1 is also involved in this regulation. *LncRNA RP5-833A20.1* could attenuate ABCA1 levels thus reduce cholesterol efflux [@B76]. It is an interesting finding here because unlike most of the lncRNA-miRNA relationships, *lncRNA RP5-833A20.1* up-regulates miR-382 thus suppressing *NFIA*. This is a conflicting result with previous findings which probably in-part because miR-382 may not be the direct downstream target of *lncRNA RP5-833A20.1*and they both participate in the regulatory network of cellular lipid*.* Both of these two lncRNAs show a regulatory function in cellular lipid mechanism and inflammation. Hu *et al.* have proven the role of *GPR119* and *NFIA* in atherosclerosis. However, it is still not clear whether the two lncRNAs could show the same function*in vivo* by regulating *in vitro* proved targets. Mechanism studies on these two important lncRNAs are rather limited. A recent RNA-seq conducted by Reddy *et al.* [@B77] compares the expression pattern of macrophages from diabetic and non-diabetic mice and a new pro-inflammatory lncRNA *E330013P06* is identified. *E330013P06*is the host gene of miR-143 and miR-145. Overexpressing *E330013P06* increases inflammatory genes (*Nos2*, *Il6* and *Ptgs2*) and scavenger receptor CD36, thus promoting foam cell formation. Knocking down *E330013P06* could only inhibit CD36 expression indicating its partial function in reversing inflammation. MiR143/145 has been found a key regulator in SMC contractile phenotype acquisition [@B78]. Loss of miR143/145 in mice results in impaired vasocontraction [@B79]. As *E330013P06* is the host gene of these two miRNAs, it may speculate that *E330013P06* plays a role in SMC phenotype regulation.

LncRNAs have also been found to be a novel regulator in the immune response which can inhibit or promote inflammatory signaling [@B80]. Carpenter*et al.*conduct a RNA-seq in macrophages stimulated with TLR2 and identify a novel lncRNA called *lincRNA-Cox2*, which locates proximal to the COX2 gene. In loss of function analysis, *lincRNA-Cox2* is proved to regulate various kinds of immune genes before (*e.g. Ccl5*) and following TLR stimulation (*e.g. Il6*). Previous studies have indicated that lncRNAs could bind to proteins to regulate transcription process [@B5]. To further understand the underlying mechanism, mass spectrometry is used to screen the possible specific proteins which *lincRNA-Cox2*interacts with. HnRNP-A/B and hnRNP-A2/B1 are finally identified. Recruitment of RNA polymerase II to the promoters of *Ccl5* is found when knocking down hnRNP-A/B and hnRNP-A2/B1, no similar trend is found in *Il6* promoters [@B80]. Therefore, it can be concluded that one of the regulatory pathways is: *lincRNA-Cox2* binds with hnRNP-A/B and hnRNP-A2/B1 to form an RNA-protein complex thus, influencing the recruitment of RNA polymerase II to regulate the transcription of inflammatory genes. Recently, Li *et al.* have also identified a similar altered lncRNA through a microarray analysis in TLR2-stimulated macrophages termed *linc1992*. *Linc1992* is widely expressed in various tissues. Meanwhile, TNF-α mRNA and protein are strongly repressed after *linc1992* knockdown. *Linc1992* expression could also be inhibited by exogenous TNF-α indicating a feedback loop between them. To understand the underlying mechanism, a similar method is used to investigate the interaction between *linc1992* and hnRNP. Only hnRNP-L could bind specifically to *linc1992*. The knocking-down of hnRNP-L could decrease TNF-α expression, and through chromatin immunoprecipitation, hnRNP-L is proved to bind directly to the promoter of TNF-α. Therefore, by binding with hnRNP-L and forming a *linc1992*/hnRNP-L complex, *linc1992* promotes the transcriptional process of TNF-α [@B81]. In this study, Li *et al.* also find that the *linc1992* knockdown could influence many other immune-associated genes which future studies may evaluate. These two studies promote the role of lncRNAs in immune response in macrophages. In particular, the hnRNP family is a significant mediator between lncRNA and its targets.

Another lncRNA found to be induced in immune response is *PTPRJ-AS1*, a long noncoding RNA on the antisense strand of the *Ptprj*. LPS could induce a transient increase in *PTPRJ-AS1*expression. The exact targets and the regulatory role of *PTPRJ-AS1* are however, still unknown [@B82].

In the end, lncRNAs may regulate macrophages or foam cells in a number of ways predominantly via inflammatory and cellular cholesterol efflux mechanisms. *LincRNA-DYNLRB2-2* and *lncRNA RP5-833A20.1*have revealed that lncRNAs could regulate foam cell formation. Studies on *lincRNA-Cox2*and*linc1992* may further focus on foam cell regulations. Meanwhile, *in vivo*studies are still limited.

LncRNA with lipid metabolism
============================

It is well known that lipid imbalance is a significant risk factor of atherosclerosis. Lipid disorders cause lipoprotein accumulation within artery walls thus triggering atherosclerosis [@B22]. Some studies have also indicated that lncRNA is involved in lipid metabolism.

*HULC* was firstly identified in hepatocellular carcinoma [@B83]. It has been described to promote proliferation and inhibit the tumour suppressor *p18*. Meanwhile, it could be a sponge of miR-372 [@B84], [@B85]. Cui*et al.*identify a novel role of *HULC* which regulates the lipid afflux in hepatoma cells. The knocking-down of *HULC* affects *PPARA* which is the transcriptional factor of ACSL1 and ACSL1 is essential in cellular long-chain fatty acid metabolism. Cui*et al.*further predict a miRNA which targets *PPARA* and identifies miR-9. *HULC* could repress miR-9 but not as a ceRNA. Instead, methylation-specific PCR and bisulfitesequencing analysis reveal that the CpG sites of miR-9 are highly methylated when overexpressing *HULC*. Meanwhile,*HULC* up-regulates DNMT1 which is a key role in inducing methylation of CpG islands in the miRNA promoter. Therefore, *HULC*targets miR-9 on transcriptional level by up-regulating DNMT1. Above all, by reducing miR-9 expression, *HULC* up-regulates *PPARA* thus increasing ACSL1 which in the end results in triglyceride and cholesterol accumulation in tumour cells [@B14]. Although *HULC* plays an important role in cell lipid afflux, no one has ever reported its roles in atherosclerosis especially in foam cells. Hu *et al.* [@B75], [@B76] find two lncRNAs in foam cells: *lncRNA-RP5-833A20.1* and *lincRNA-DYNLRB2-2* which could both regulate foam cell cholesterol efflux and inflammation. Meanwhile, their down-stream targets have been shown to regulate plasma lipid and atherosclerosis which indicate their important role in regulating atherosclerosis progression. *SRA* was firstly identified as a RNA coactivator involved in steroid receptor-dependent gene expression [@B18]. Other studies also indicate that *SRA* is involved in adipogenesis [@B86], tumourigenesis [@B87] and myogenesis [@B88]. Liu *et al.* further show its role in SRA knockout mice and reveal that following high-fat diet, SRA knockout mice result in reduced adiposity with decreased body fat. Moreover, decreased lipogenesis-associated genes such as*Ppara*,*Pparg*, *Fabp4* and *Lipe*are found [@B89]. Considering all above functions, it may be speculated that *SRA* is involved in lipid metabolism. Halley*et al.*[@B90] identify an antisense in the *ApoA1* locus called *APOA1-AS*. The knocking-down of *APOA1-AS* with siRNA could increase *ApoA1 in cis*. Chromatin immunoprecipitation analysis shows that after knocking down *APOA1-AS*, H3K4 trimethylation is active around *ApoA1* promoter, and H3K27 trimethylation is found to be inactive around *ApoA1*, *ApoA4*, and *ApoC3*. Meanwhile, LSD1 and SUZ12 recruitments are reduced. *APOA1-AS* could regulate *ApoA1* by guiding LSD1 and SUZ12 to the promoter of *ApoA1* which causes decreased H3K4 trimethylation and increased H3K27 trimethylation. As *ApoA1* is important in lipid efflux and retains atherosclerosis, *APOA1-AS* might be a risk factor in lipid accumulation.

LncRNAs show their potential function in lipid metabolism. Studies have shown that some important lipid transport and lipogenesis genes are regulated in gain and loss of function analysis. However, until now, studies have only discussed this issue on the cellular level. *In vivo* function studies of lncRNA in plasma cholesterol, triglycerides or lipoproteins are still lacking.

LncRNAs as cardiovascular biomarkers
====================================

Circulating biomarkers have greatly improved the diagnosis accuracy of acute coronary disease. The identified biomarkers today are mostly proteins and peptides. MiRNAs have been discovered to include in the diagnosis and prognosis of patients with myocardial infarction and heart failure [@B91]. As lncRNAs are involved in various cardiovascular disease progresses, it has also been potential biomarkers in cardiovascular disease [@B92].

*ANRIL* has long been investigated as a potential biomarker as it is found increased in plaque and plasma of atherosclerosis patients [@B30], [@B93]. In a cohort study, three of the *ANRIL* transcripts (*NR_003529, DQ485454*, and *EU741058*) are investigated. It reveals that *NR_003529*and*DQ485454* increase in carriers of the risk SNPs individuals, while *DQ485454*stays unaffected indicating that different *ANRIL* transcripts may vary in their functions. Moreover, *NR_003529* and *DQ485454* correlate with severity of atherosclerosis [@B30]. Kumarswamy *et al.* identify a differently expressed lncRNA in patients\' plasma with and without cardiac remodelling following myocardial infarction. A lincRNA called *LIPCAR* is consistently detectable and increases significantly in patients with cardiac remodelling. It is further evaluated in another two studies, one of which is a cohort and the other is a case-control study. *LIPCAR* is found higher both in ischemic heart failure and non-ischemic heart failure. Higher *LIPCAR* level is associated with cardiovascular mortality. In the latter study, *LIPCAR*is further evaluated and after adjusting for other risk factors, *LIPCAR* is still an independent predictor of 3-year cardiovascular death [@B94]. Vausort *et al.* further compare five plasma-detectable lncRNAs between myocardial infraction and healthy volunteers, and find four differently expressed lncRNAs including *HIF1αAS2*, *KCNQ1OT*, *MALAT1* which are up-regulated and *ANRIL* which is down-regulated. *MIAT* does not differ between the two groups. Although they are induced in myocardial infraction, only *KCNQ1OT1* and *ANRIL* show predictive values of LV dysfunction [@B95].

The clinical use of lncRNA as biomarkers in atherosclerosis and cardiovascular disease seems constraint until now probably due to the relatively low level of lncRNAs in plasma and the weak predictive effect (Summary See Table [2](#T2){ref-type="table"}). It is obvious that the study on lncRNAs as biomarkers is just starting. *ANRIL* has shown to be induced and associated with atherosclerosis and LV dysfunction, *LIPCAR*, *KCNQ1OT* and *MIAT* reveal to predict cardiovascular outcome. Whether the vast amount of unannotated lncRNAs are better predictive biomarkers than the existing ones are to be determined. The stability and detectability of lncRNAs in plasma also need to be taken into account [@B92].

Conclusion and Perspective
==========================

In conclusion, long noncoding RNAs are newly identified as vital regulators in multiple biological processes. Recognition of their roles in human disease has unveiled new mechanistic understanding and will lead to novel diagnostic and therapeutic approaches. While recent advances in lncRNA studies of cardiovascular disease indicate progress toward incorporation of lncRNAs into the pre-existing miRNA-mRNA-protein regulatory network, many pressing questions persist.

A challenge for research in this area is that most of the available data are *in vitro* findings. Poor sequence conservation and challenging gain-and-loss method still hinder *in vivo*studies. Specifically, for the well-attested functional lncRNA like *ANRIL*and *MALAT1*, future studies may focus on further elucidating their signaling pathways *in vivo*. Another remaining challenge will be to optimize the techniques for lncRNA capture and identification in biofuluids, which may consequently shield the potential clinical values of lncRNAs as biomarkers.
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![Work pattern of LncRNA-miRNA crosstalk. A. LncRNA acts as a ceRNA. By working as a sponge, lncRNA traps miRNA and inhibits miRNA\'s repression effect; B. LncRNA acts as the host gene of miRNA. MiRNA is encoded by lncRNA and alternations on lncRNA expression will concomitantly influence miRNA transcription; C. LncRNA targets the promoter of miRNA. *HULC* guides DNMT1 to the promoter of miRNA thus inducing methylation of CpG islands in the miRNA promoter.](ijbsv12p0898g002){#F2}

###### 

Summary of atherosclerosis-related lncRNAs

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Cell type/ process   lncRNA                          Class       Location             Roles / targets               Function
  -------------------- ------------------------------- ----------- -------------------- ----------------------------- ---------------------------------------------------------------------
  SMC                  *ANRIL*^\[28-35\]^              Antisense   Nucleus              Guide, scaffold*CDKN2A/B*     Proliferation ↑/ adhesion ↑/ apoptosis ↓

                       *H19 lincRNA*^\[42-44\]^        LincRNA     Cytoplasm            Precursor, ceRNA\             Unknown
                                                                                        miR-675\                      
                                                                                        Let-7 miRNA                   

                       *Lnc-Ang362*^\[45\]^            LincRNA     Unknown              Precursor\                    Proliferation ↑
                                                                                        miR-221/222                   

                       *SENCR*^\[52\]^                 Antisense   Cytoplasm            *Myocd/ Mdk/ Ptn*             Synthetic SMC ↑

                       *LincRNA-p21*^\[20\]^           LincRNA     Nucleus              RNA-protein\                  Proliferation ↓ / apoptosis ↑
                                                                                        *p53*                         

                       *HAS2-AS1*^\[49\]^              Antisense   Unknown              Guide\                        Hyaluronan ↑
                                                                                        *HAS2*                        

                       *HIF1α-AS1*^\[50\]^             Antisense   Unknown              Unknown                       Apoptosis ↑

                       *LncRNA-GAS5*^\[51\]^           LincRNA     Cytoplasm            RNA-protein\                  Proliferation ↓/ migration ↓
                                                                                        Annexin A2                    

  EC                   *NRON*^\[54-57\]^               LincRNA     Cytoplasm            Decoy, scaffold\              Proliferation ↓/ tube formation ↓/ migration ↓
                                                                                        *NFAT*                        

                       *Tie-1AS*^\[59\]^               Antisense   Cytoplasm            lncRNA-mRNA\                  Tube formation ↓
                                                                                        *Tie-1*                       

                       *Terminator*^\[60\]^            LincRNA     Nucleus              Unknown                       Pluripotent maintenance

                       *Alien*^\[60\]^                 LincRNA     Nucleus+ Cytoplasm   Unknown                       Cell adhesion/ extracellular matrix remodelling/ vessel development

                       *Punisher*^\[60\]^              Antisense   Nucleus+ Cytoplasm   Unknown                       Proliferation ↑/ tube formation ↑

                       *MALAT1*^\[64-66\]^             LincRNA     Nucleus              *Cyclins A2, B1/B2*           Angiogenesis ↑/ diabetic vascular damage ↑

                       *MIAT*^\[69\]^                  LincRNA     Nucleus              ceRNA\                        Angiogenesis ↑/ diabetic vascular damage ↑
                                                                                        miR-150                       

                       *LincRNA-p21*^\[70\]^           LincRNA     Nucleus              ceRNA\                        Apoptosis ↑
                                                                                        miR-130b                      

                       *FLJ11812*^\[71\]^              Sense       Unknown              ceRNA\                        Autophagy ↑
                                                                                        miR-4459                      

                       *sONE*^\[72,74\]^               Antisense   Nucleus+ Cytoplasm   *eNOS*                        eNOS ↓

  Macrophage           *LincRNA-DYNLRB2-2*^\[75\]^     LincRNA     Uknown               *GPR119*                      Inflammation ↓/ cholesterol efflux ↑

                       *LncRNA RP5-833A20.1*^\[76\]^   Antisense   Nucleus+ Cytoplasm   miR-382                       Inflammation ↑/ cholesterol efflux ↓

                       *E330013P06*^\[77\]^            LincRNA     Unknown              Unknown                       Foam cell formation ↑

                       *Linc1992*^\[81\]^              LincRNA     Unknown              RNA-Protein\                  TNF-α expression ↑
                                                                                        hnRNP-L                       

                       *LincRNA-Cox2*^\[80\]^          LincRNA     Nucleus+ Cytoplasm   RNA-Protein\                  Immune related genes like *Ccl5*, *Il-6*
                                                                                        hnRNP-A/B & hnRNP-A2/B1       

                       *PTPRJ-AS1*^\[82\]^             Antisense   Cytoplasm            Unknown                       Unknown

  Lipid metabolism     *HULC*^\[14\]^                  LincRNA     Cytoplasm            Guide\                        Lipid afflux ↑
                                                                                        miR-9                         

                       *SRA*^\[89\]^                   Sense       Nucleus              Coactivator\                  Adiposity ↑
                                                                                        *Ppara, Pparg, Fabp4, Lipe*   

                       *APOA1-AS*^\[90\]^              Antisense   Unknown              Guide\                        Lipid afflux ↑
                                                                                        *ApoA1*                       
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

###### 

Summary of lncRNAs as cardiovascular biomarkers

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  LncRNA                           Disease                        Application                                        Study type        Study size                      Follow-up
  -------------------------------- ------------------------------ -------------------------------------------------- ----------------- ------------------------------- -----------
  *ANRIL (NR_003529 & DQ485454)*   CAD^\[30\]^                    Risk factor                                        Cross-sectional   1134 atherosclerosis patients   None

  *ANRIL (all transcripts)*        MI^\[95\]^                     LV dysfunction predictors                          Cohort            414 MI; 86 healthy              4 month

  *LIPCAR*                         MI & HF^\[94\]^                Cardiac death and cardiac remodelling predictors   Cohort            246 MI                          12 months

  Cohort                           344 HF                         3 years                                                                                              

  Case-control                     99 died and 99 alive from HF   3 years                                                                                              

  *KCNQ1OT*                        MI^\[95\]^                     LV dysfunction predictors                          Cohort            414 MI; 86 healthy              4 month

  *HIF1αAS2*\                      MI^\[95\]^                     None                                               Cohort            414 MI; 86 healthy              4 month

  *MALAT1*\                        MI^\[95\]^                     None                                               Cohort            414 MI; 86 healthy              4 month

  *MIAT*\                          MI^\[95\]^                     None                                               Cohort            414 MI; 86 healthy              4 month

  *MIAT*                           MI^\[68\]^                     Risk factor                                        Case-control      3464 MI; 3819 healthy           None
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
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